QIAGEN Asia to supply RNAi and related solutions to China’s premier provider for drug discovery and development services Shanghai, China, May 29, 2008 — QIAGEN today announced that it has been selected by Shanghai Biochip Corporation (SBC) as a primary partner to supply various small interfering RNA (siRNA) library sets. SBC will use these library sets for setting up the first siRNA high-throughput screening center in China.

The newest generation of CARESTREAM Digital Dashboard that includes proactive notification for system events via e-mail or text messaging will be available worldwide on June 19. The digital dashboard, which supports CARESTREAM RIS/PACS and CARESTREAM Information Management Solutions, offers system administrators a convenient way to proactively monitor equipment performance, storage utilization and user volumes—from virtually anywhere. The digital dashboard also enables administrators to verify network communication of other vendors’ devices.

Hanoi, Vietnam – June 5 19, 2008 – QIAGEN was featured this week for its efforts to eliminate cervical cancer at the 14th annual Global Summit of Women in Hanoi, Vietnam. CEO Peer Schatz came to this prominent international platform to issue a call to other leaders in business, NGOs and governments to join him and campaign to create a cervical-cancer-free world.

Abbott announced that it has submitted an application forSeizo Hanbai Shonin (Marketing Authorization License) to Japan's Ministry of Health, Labour and Welfare (MHLW)/ Pharmaceuticals and Medical Devices Agency (PMDA) to gain approval for its XIENCE™ V Everolimus Eluting Coronary Stent System to treat coronary artery disease. The Shonin application for XIENCE V consisted of safety and efficacy data from the SPIRIT III clinical trial, including data from a Japanese patient population. As previously reported, results from the SPIRIT III U.S. pivotal clinical trial demonstrated the superiority of XIENCE V over Boston Scientific's TAXUS® paclitaxel-eluting coronary stent system in the primary endpoint of in-segment late loss at eight months.

GE Healthcare and InSightec Ltd. announced today that a new study suggests that women with clinically significant uterine fibroids (UF) have poorer health status and more associated health conditions than their counterparts.  The study, which appears in the June issue of Fertility and Sterility notes that nearly half a million insured women are living with clinically significant UF and may be living with other debilitating healthcare conditions including anemia and endometriosis.

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, today announced the company and its employees have together made cash donations of over RMB1.0 million through the Red Cross Society of China to help support the Sichuan earthquake disaster relief. In addition, Mr. Xu Hang and Mr. Li Xiting, Mindray's co-chief executive officers, together donated a combined value of over RMB3.2 million in high-quality, portable multi-parameter patient monitoring devices, which they purchased from the company at distributor list prices.

For the seventh year in a row, GE Healthcare has won Omega Management Group’s prestigious NorthFace ScoreBoard Award™ for excellence in customer satisfaction and loyalty in servicing anesthesia machines and patient monitors. Omega Management Group surveys approximately 100 GE customers each quarter to measure satisfaction and loyalty levels on a 5-point scale. NorthFace ScoreBoard Award recipients are companies who, based on survey responses from their own customers, achieved a 4.0 or above out of a possible 5.0 in key service categories such as excellence in field service, technical support, parts ordering process and technical training, among others.